Robert Nelsen

Robert Nelsen

Cofounder, ARCH Venture Partners

Robert Nelsen is a cofounder and managing director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing, and development of more than 100 companies, including 27 that have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Beam Therapeutics (BEAM); Karuna Therapeutics (KRTX); Lyell Immunopharma; Array BioPharma (ARRY); Unity Biotechnology (UBX); Hua Medicine (2552:HK); Vir Biotechnology (VIR); Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL; Gossamer Bio (GOSS); Ikaria; Kythera Biopharmaceuticals (KYTH); Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics (RUBY); Syros Pharmaceuticals (SYRS); Sana Biotechnology; KSQ Therapeutics; NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Fate Therapeutics (FATE); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Editas (EDIT); 10x Genomics; Semma Therapeutics; IDUN Pharmaceuticals;; Sienna Biopharmaceuticals (SNNA); and Everyday Learning Corporation.

Nelsen is a director of Vir Bio, GRAIL, Sana Biotechnology, Beam Therapeutics, Unity Biotechnology, and Denali Therapeutics, and serves as chairman of Hua Medicine, among others. He previously served as a trustee of the Fred Hutchinson Cancer Research Institute and the Institute for Systems Biology, and was a director of the National Venture Capital Association. Nelsen holds a BS from the University of Puget Sound with majors in economics and biology and an MBA from Chicago Booth.

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.